- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -
See more here:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Recommendation and review posted by Fredricko
